IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract

IMGT/mAb-DB ID	829
INN	apitegromab
INN Number	11471
INN Prop. List	123 (2020)
INN Rec. List	85 (2021)
Common name	SRK-015, SRK015, SRK 015
Proprietary name
Species	Homo sapiens
IMGT receptor type	IG
Format (legend)
Receptor identification	IgG4 - lambda
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB	11471
IMGT/3Dstructure-DB
Specificity target name and species	pro-MSTN (pro-growth differentiation factor 8, pro-GDF8, pro-myostatin, pro-GDF-8) [Homo sapiens]
Development Technology
Origin clone species
Origin clone name

Company	Scholar Rock (Cambridge MA USA)
Expression system	CHO (Chinese Hamster Ovary) cells
Application	Therapeutic
Clinical domain	Genetic disorder
Mechanism of action
Clinical indication	Spinal muscular atrophy (SMA)
Development status	Phase II
Regulatory agency status and year	Orphan drug (EMA designation) December 14, 2018 Orphan drug (FDA designation) March 22, 2018

Clinical trials
Authority decisions
External links
Biosimilars

Format legend:

IMGT/mAb-DB query | IMGT/mAb-DB documentation